Skip to content

A Clinical Study to Assess the Effectiveness of Siddha Medicines Sathakuppai Chooranam and Sanjeevi Thailam in Treating Generalized Anxiety Disorder

SINGLE CENTRIC PHASE II RANDOMIZED CONTROLLED OPEN CLINICAL TRIAL IN VIGAARA PITHAM (GENERALISED ANXIETY DISORDER) WITH THE SIDDHA MEDICINE SATHAKUPPAI CHOORANAM (INTERNALLY) AND SANJEEVI THAILAM (EXTERNALLY) - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/105243
Enrollment
84
Registered
2026-03-02
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F411- Generalized anxiety disorder

Interventions

Intervention1: SATHAKUPPAI CHOORANAM (Internal): Dosage : Viral Alavu (3 gm) Adjuvant : Hot Water Time of Administration : Twice a Day (Morning and Evening) Duration : 20 Days Intervention2: SANJEEVI

Sponsors

Dr S MOAHMED AJMAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with GAD - 7 total score range between greater than 5 and less than 21 fulfilling DSM V diagnostic criteria for GAD were included in the study Excessive anxiety and Worry (Core Criterion) Difficulty in controlling the worry Restlessness or felling keyed up or on edge, Easily fatigued (feeling tired frequently), Difficulty concentrating or mind going blank, irritability, muscle tension, sleep disturbance (difficulty falling or staying asleep, or restless, and unsatisfying sleep) Significant distress

Exclusion criteria

Exclusion criteria: Age greater than 60 Years Patients who are taking Psychotropic drugs and substance abuse like alcohol etc., Patients not fulfilling the GAD criteria (other Psychiatric disorders) Other medical conditions like Diabetes Mellitus, Hypertension, Hypo thyroidism, Hyper thyroidism and any other systemic illness participants will be excluded clinically or based on available medical reports Pregnant and Lactating Women

Design outcomes

Primary

MeasureTime frame
Primary Outcome is mainly assessed by Reduction in clinical symptoms after treatmentTimepoint: 20 days

Secondary

MeasureTime frame
Secondary Outcome is mainly assessed by Comparing the Generalized Anxiety Disorder 7 Scale (GAD-7) & Hamilton Anxiety Rating Scale (HAM-A) in pre & post treatment which ensures the wellness of the patient.Timepoint: 20 days

Countries

India

Contacts

Public ContactDr K SUDHAMATHI PUSHPARAJ

GOVERNMENT SIDDHA MEDICAL COLLEGE, ARUMBAKKAM, CHENNAI

sudhamathipushparaj@gmail.com9445118473

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026